WO2010085100A3 - 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 - Google Patents

신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 Download PDF

Info

Publication number
WO2010085100A3
WO2010085100A3 PCT/KR2010/000395 KR2010000395W WO2010085100A3 WO 2010085100 A3 WO2010085100 A3 WO 2010085100A3 KR 2010000395 W KR2010000395 W KR 2010000395W WO 2010085100 A3 WO2010085100 A3 WO 2010085100A3
Authority
WO
WIPO (PCT)
Prior art keywords
transmembrane domain
cellular transmembrane
transduction system
same
system containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/000395
Other languages
English (en)
French (fr)
Other versions
WO2010085100A2 (ko
Inventor
김재일
박진석
김현진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gwangju Institute of Science and Technology
Anygen Co Ltd
Original Assignee
Gwangju Institute of Science and Technology
Anygen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gwangju Institute of Science and Technology, Anygen Co Ltd filed Critical Gwangju Institute of Science and Technology
Publication of WO2010085100A2 publication Critical patent/WO2010085100A2/ko
Publication of WO2010085100A3 publication Critical patent/WO2010085100A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템에 관한 것이다. 본 발명의 세포막 투과 도메인은 기존의 바이러스로부터 유래된 펩타이드 또는 서열 특이적으로 설계된 펩타이드들과 비교할 때, 유전적인 면역 문제 또는 세포 독성에 있어서 매우 우수한 효과를 나타낼 수 있기 때문에, 부작용의 우려 없이 임상적으로 인체에 적용할 수 있으며, 여러 질병에 관한 진단 및 신약 개발에도 활용할 수 있다.
PCT/KR2010/000395 2009-01-21 2010-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 Ceased WO2010085100A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090004863A KR101169030B1 (ko) 2009-01-21 2009-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
KR10-2009-0004863 2009-01-21

Publications (2)

Publication Number Publication Date
WO2010085100A2 WO2010085100A2 (ko) 2010-07-29
WO2010085100A3 true WO2010085100A3 (ko) 2010-11-11

Family

ID=42356331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000395 Ceased WO2010085100A2 (ko) 2009-01-21 2010-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템

Country Status (2)

Country Link
KR (1) KR101169030B1 (ko)
WO (1) WO2010085100A2 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2784081B1 (en) * 2011-11-23 2017-02-01 Procell Therapeutics Inc. Development of novel macromolecule transduction domain with improved cell permeability and method for using same
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
EP2875826B1 (en) 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Composition for preventing or treating sepsis
ES2981865T3 (es) * 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
KR102201429B1 (ko) 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
TWI655204B (zh) 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
WO2014046481A1 (ko) 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
KR101636542B1 (ko) * 2012-10-09 2016-07-07 한양대학교 산학협력단 인간 ｎｌｂｐ 유래의 ｎｐ12 폴리펩티드 또는 ｎｐ21 폴리펩티드를 포함하는 세포 투과 펩티드 및 이를 이용한 카고 전달 시스템
KR101475744B1 (ko) * 2013-03-08 2014-12-24 서울대학교산학협력단 세포 투과 펩타이드
WO2014171792A1 (ko) 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
US9757473B2 (en) 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
CN105899224B (zh) 2013-10-23 2019-12-13 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
KR102166549B1 (ko) * 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
WO2016006744A1 (ko) * 2014-07-11 2016-01-14 주식회사 프로셀테라퓨틱스 세포 내 분자 전송 펩티드를 이용한 경피 전달용 펩티드-sirna 복합체 및 이의 용도
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
KR20250073577A (ko) 2015-05-26 2025-05-27 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
WO2017003267A1 (ko) 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
WO2021234550A1 (ko) 2020-05-19 2021-11-25 애니젠 주식회사 신규 뉴클레오린-결합 펩타이드 및 이의 용도
KR102848255B1 (ko) 2021-05-18 2025-08-25 에이치엘비펩 주식회사 뉴클레오린-결합 펩타이드를 포함하는 항바이러스 조성물
WO2023090935A1 (ko) * 2021-11-18 2023-05-25 애니젠 주식회사 뉴클레오린에 특이적으로 결합하는 agm 펩타이드를 제조하는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154188A1 (en) * 2002-03-29 2005-07-14 Dae-You Kim Cytoplasmic tranduction peptides and uses thereof
KR100859972B1 (ko) * 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154188A1 (en) * 2002-03-29 2005-07-14 Dae-You Kim Cytoplasmic tranduction peptides and uses thereof
KR100859972B1 (ko) * 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABDULRASHEED A. ALABI ET AL.: "Portability of paddle motif function and pharmacology in voltage sensors", NATURE, vol. 450, 15 November 2007 (2007-11-15), pages 370 - 375 *
HOI JONG JUNG ET AL.: "Solution Structure and Lipid Membrane Partitioning of VSTx1, an Inhibitor of the KvAP Potassium Channel", BIOCHEMISTRY, vol. 44, 26 April 2005 (2005-04-26), pages 6015 - 6023 *
YOUXING JIANG ET AL.: "X-ray structure of a voltage-dependent K1+ channel", NATURE, vol. 423, 1 May 2003 (2003-05-01), pages 33 - 41 *

Also Published As

Publication number Publication date
KR101169030B1 (ko) 2012-07-26
KR20100085527A (ko) 2010-07-29
WO2010085100A2 (ko) 2010-07-29

Similar Documents

Publication Publication Date Title
WO2010085100A2 (ko) 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
WO2012038061A3 (en) Nanocapsules containing microemulsions
WO2009108730A3 (en) Forms of rifaximin and uses thereof
WO2010069532A8 (en) Antibodies against human angiopoietin 2
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
EP3050876A3 (en) Kinase modulators
IL219876A (en) Antibodies against human 1h-7b or its fragment, preparations containing them and their use in the preparation of drugs
WO2009024677A3 (fr) Utilisation d ' acide hyaluronique pour la preparation de compositions destinees a l' amelioration de la fonction de protection de la peau, de l' oeil et des muqueuses
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2010138194A3 (en) Immunomodulatory agent-polymeric compounds
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
WO2011077043A3 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
WO2011106376A3 (en) Use of microvesicles in the treatment of medical conditions
WO2008141308A3 (en) Gene expression and pain
PH12013500337A1 (en) Dual variable domain immunoglobulins and uses thereof
EP2841107A4 (en) CYTOTOXIC ACTIVITIES DISPOSED OF HIV RELEASING MOLECULES (CDM-HS), CYTOTOXIC EFFECT AGAINST HUMAN IMMUNE WEAKAGE VIRUS AND METHOD OF USE
WO2011060363A3 (en) Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
WO2010144477A3 (en) Sulfonylurea modulators of endothelin receptor
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
IL209371A0 (en) C-ring-substituted pregn-4-ene-21,17-carbolactone, and pharmaceutical preparations comprising the latter
WO2010012940A3 (fr) Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
WO2011163512A3 (en) Cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733653

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10733653

Country of ref document: EP

Kind code of ref document: A2